Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control
| Autor: | Chung-Yao Hsu, Che Ming Jack Hu, Kai-Chieh Yang, Vicky Shih, Hsiao-Han Tsai, Jung-Chen Lin |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Coronavirus disease 2019 (COVID-19)
medicine.drug_class Nanodecoy Pharmaceutical Science Nanotechnology 02 engineering and technology Virus Replication Nanosponge Antiviral Agents 030226 pharmacology & pharmacy 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Host-targeted antiviral Intervention (counseling) Pandemic Animals Humans Medicine Antiviral state Pandemics Pathogen business.industry COVID-19 Antivirals 021001 nanoscience & nanotechnology Clinical trial Virus Diseases Drug delivery Host-Pathogen Interactions Nanoparticles Original Article Nanocarriers Antiviral drug 0210 nano-technology business |
| Zdroj: | Drug Delivery and Translational Research |
| ISSN: | 2190-3948 2190-393X |
| Popis: | Graphical abstract The COVID-19 pandemic's high mortality rate and severe socioeconomic impact serve as a reminder of the urgent need for effective countermeasures against viral pandemic threats. In particular, effective antiviral therapeutics capable of stopping infections in its tracks is critical to reducing infection fatality rate and healthcare burden. With the field of drug delivery witnessing tremendous advancement in the last two decades owing to a panoply of nanotechnology advances, the present review summarizes and expounds on the research and development of therapeutic nanoformulations against various infectious viral pathogens, including HIV, influenza, and coronaviruses. Specifically, nanotechnology advances towards improving pathogen- and host-targeted antiviral drug delivery are reviewed, and the prospect of achieving effective viral eradication, broad-spectrum antiviral effect, and resisting viral mutations are discussed. As several COVID-19 antiviral clinical trials are met with lackluster treatment efficacy, nanocarrier strategies aimed at improving drug pharmacokinetics, biodistributions, and synergism are expected to not only contribute to the current disease treatment efforts but also expand the antiviral arsenal against other emerging viral diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink